1
|
Abstract
Accessory parotid gland (APG) tumors account for 1% to 7% of all parotid gland neoplasms but are more likely to be malignant than main parotid gland tumors. Management of APG neoplasms entails surgical excision. Four primary approaches to resection have been described in the literature with varying facial nerve outcomes. We report a case of a 4-cm APG pleomorphic adenoma utilizing a transoral approach for excision without postoperative facial nerve injury. A transoral approach is known to mitigate patients' cosmetic concerns; however, prior reports utilized endoscopic assistance on patients with smaller tumors. We conclude that large APG tumors can be excised through a transoral approach without undue risk to the distal facial nerves, though this transoral approach ultimately may not be appropriate for malignant neoplasms or difficult dissections.
Collapse
Affiliation(s)
- Rohith S Voora
- University of California, San Diego School of Medicine, La Jolla, CA, USA
- Division of Head and Neck Surgery, Department of Surgery, San Diego, CA, USA
| | - Joshua Stramiello
- Division of Head and Neck Surgery, Department of Surgery, San Diego, CA, USA
| | - Emily Funk
- Division of Head and Neck Surgery, Department of Surgery, San Diego, CA, USA
| | - Joseph Califano
- Division of Head and Neck Surgery, Department of Surgery, San Diego, CA, USA
| |
Collapse
|
2
|
Voora RS, Panuganti B, Califano J, Coffey C, Guo T. Patterns of Lymph Node Metastasis in Parotid Cancer and Implications for Extent of Neck Dissection. Otolaryngol Head Neck Surg 2023; 168:1067-1078. [PMID: 36939401 DOI: 10.1002/ohn.167] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 07/27/2022] [Accepted: 09/10/2022] [Indexed: 01/21/2023]
Abstract
OBJECTIVE The role and extent of neck dissection in primary parotid cancer are controversial. Herein, we characterize patterns of lymph node metastasis in parotid cancer. STUDY DESIGN Retrospective analysis. SETTING National Cancer Database. METHODS Patients with the 6 most common histologic subtypes of parotid cancer were selected. Primary outcomes were the distribution of positive lymph nodes by level and overall survival assessed by Cox analysis. Secondary outcomes included predictors of extended lymph node involvement (≥3 lymph nodes or Level IV/V involvement), via logistic regression. RESULTS Six thousand nine hundred seventy-seven patients with acinic cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, carcinoma ex pleomorphic adenoma (CExPA), mucoepidermoid carcinoma, and salivary duct carcinoma (SDC) were included. Among cN0 patients, 8.2% of low-grade tumor patients had occult nodal metastasis versus 30.9% in high-grade tumor patients. Elective neck dissection was not associated with an overall survival benefit (adjusted hazard ratio: 1.10; 0.94-1.30, p = .238). Among cN+ tumors, CExPA (odds ratio [OR]: 1.88, 1.05-3.39, p = .034) and high-grade pathology (OR: 3.03, 1.87-4.93, p < .001) were predictive of having ≥3 pathologic nodes. CExPA (OR: 2.13, 1.22-3.72, p = .008), adenocarcinoma (OR: 1.60, 1.11-2.31, p = .013), SDC (OR: 1.92, 1.17-3.14, p < .01), and high-grade pathology (OR: 3.61, 2.19-5.97, p < .001) were predictive of Level IV/V neck involvement. CONCLUSIONS In parotid malignancy, nodal metastasis distribution is dependent on histology and grade. High-grade tumors and certain histologies (SDC and adenocarcinoma) had a higher incidence of occult nodes. Comprehensive neck dissection should also be considered for node-positive high-grade tumors, SDC, and adenocarcinoma.
Collapse
Affiliation(s)
- Rohith S Voora
- University of California, San Diego School of Medicine, La Jolla, California, USA.,Department of Otolaryngology-Head and Neck Surgery, University of California, San Diego School of Medicine, La Jolla, California, USA
| | - Bharat Panuganti
- Department of Otolaryngology-Head and Neck Surgery, University of California, San Diego School of Medicine, La Jolla, California, USA.,Gleiberman Head and Neck Cancer Center, Moores Cancer Center, La Jolla, California, USA
| | - Joseph Califano
- Department of Otolaryngology-Head and Neck Surgery, University of California, San Diego School of Medicine, La Jolla, California, USA.,Gleiberman Head and Neck Cancer Center, Moores Cancer Center, La Jolla, California, USA
| | - Charles Coffey
- Department of Otolaryngology-Head and Neck Surgery, University of California, San Diego School of Medicine, La Jolla, California, USA.,Gleiberman Head and Neck Cancer Center, Moores Cancer Center, La Jolla, California, USA
| | - Theresa Guo
- Department of Otolaryngology-Head and Neck Surgery, University of California, San Diego School of Medicine, La Jolla, California, USA.,Gleiberman Head and Neck Cancer Center, Moores Cancer Center, La Jolla, California, USA
| |
Collapse
|
3
|
Qiao EM, Guram K, Kotha NV, Voora RS, Qian AS, Ahn GS, Kalavacherla S, Pindus R, Banegas MP, Stewart TF, Johnson ML, Murphy JD, Rose BS. Association Between Primary Care Use Prior to Cancer Diagnosis and Subsequent Cancer Mortality in the Veterans Affairs Health System. JAMA Netw Open 2022; 5:e2242048. [PMID: 36374497 PMCID: PMC9664263 DOI: 10.1001/jamanetworkopen.2022.42048] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
IMPORTANCE Primary care physicians (PCPs) are significant contributors of early cancer detection, yet few studies have investigated whether consistent primary care translates to improved downstream outcomes. OBJECTIVE To evaluate the association of prediagnostic primary care use with metastatic disease at diagnosis and cancer-specific mortality (CSM). DESIGN, SETTING, AND PARTICIPANTS This cohort study used databases with primary care and referral linkage from multiple Veterans' Affairs centers from 2004 to 2017 and had a 68-month median follow-up. Analysis was completed between July 2021 and September 2022. Participants included veterans older than 39 years who had been diagnosed with 1 of 12 cancers. Inclusion criteria included known clinical staging, survival follow-up, cause of death, and receiving care at the Veterans Affairs health system (VA). EXPOSURES Prediagnostic PCP use, measured in the 5 years prior to diagnosis. PCP visits were binned into none (0 visits), some (1-4 visits), and annual (5 visits). MAIN OUTCOMES AND MEASURES Metastatic disease at diagnosis, cancer-specific mortality (CSM) for entire cohort and stratified by tumor subtype. RESULTS Among 245 425 patients representing 12 tumor subtypes, mean age was 65.8 (9.3) years, and the cohort skewed male (97.6%), and White (76.1%), with higher levels of comorbidity (58.6% with Charlson Comorbidity Index scores ≥2). Compared with no prior visit, some PCP use was associated with 26% decreased odds of metastatic disease at diagnosis (odds ratio [OR], 0.74; 95% CI, 0.71-0.76; P < .001) and 12% reduced risk of CSM (subdistribution hazard ratio [SHR], 0.88; 95% CI, 0.86-0.89; P < .001). Annual PCP use was associated with 39% decreased odds of metastatic disease (OR, 0.61; 95% CI, 0.59-0.63; P < .001) and 21% reduced risk of CSM (SHR, 0.79; 95% CI, 0.77-0.81; P < .001). Among tumor subtypes, prostate cancer had the largest effect size for prior PCP use on metastatic disease at diagnosis (OR for annual use, 0.32; 95% CI, 0.30-0.35; P < .001) and CSM (SHRfor annual use, 0.51; 95% CI, 0.48-0.55; P < .001). CONCLUSIONS AND RELEVANCE In this cohort study, increased primary care use before cancer diagnosis was associated with significant decreases in metastatic disease at diagnosis and cancer-related death, with potentially the greatest difference from annual use. PCPs play a vital role in cancer prevention, and additional resources should be allocated to assist these physicians.
Collapse
Affiliation(s)
- Edmund M. Qiao
- VA San Diego Health Care System, La Jolla, California
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Kripa Guram
- VA San Diego Health Care System, La Jolla, California
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Nikhil V. Kotha
- VA San Diego Health Care System, La Jolla, California
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Rohith S. Voora
- VA San Diego Health Care System, La Jolla, California
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Alexander S. Qian
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Grace S. Ahn
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Sandhya Kalavacherla
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Ramona Pindus
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Matthew P. Banegas
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Tyler F. Stewart
- Division of Hematology-Oncology, Department of Internal Medicine, University of California, San Diego, La Jolla
| | - Michelle L. Johnson
- Department of Family Medicine and Public Health, University of California, San Diego, La Jolla
| | - James D. Murphy
- VA San Diego Health Care System, La Jolla, California
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| | - Brent S. Rose
- VA San Diego Health Care System, La Jolla, California
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla
| |
Collapse
|
4
|
Voora RS, Qian AS, Kotha NV, Qiao EM, Meineke M, Murphy JD, Orosco RK. Frailty Index as a Predictor of Readmission in Patients With Head and Neck Cancer. Otolaryngol Head Neck Surg 2022; 167:89-96. [PMID: 34520305 DOI: 10.1177/01945998211043489] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE To evaluate the predictive utility of the Hospital Frailty Risk Score (HFRS), a stratification tool based on the ICD-10 (International Classification of Disease, Tenth Revision), and other risk factors for 30-day readmissions and mortality in a nationally representative cohort. STUDY DESIGN Retrospective database review. SETTING Nationwide Readmissions Database (2017). METHODS Patients with head and neck cancer who underwent major surgical procedures were identified from the 2017 Nationwide Readmissions Database, representing 116 medical centers nationwide. Bivariate and multivariable logistic regression methods were used to identify factors associated with unplanned 30-day readmission, 30-day readmission mortality, and increased length of hospital stay. RESULTS A total of 14,420 patients underwent major head and neck cancer surgery. Unplanned readmission occurred in 11% of patients. The most common reasons for unplanned readmission were procedural complications (26.5%), sepsis (7.3%), and respiratory failure (3.9%). Elevated frailty index (HFRS ≥5) was identified in 22% of patients. Frailty was associated with higher 30-day readmission rates (18.0% vs 9.5%, P < .01), which held on multivariate modeling (odds ratio [OR], 1.59 [95% CI, 1.37-1.85]). Frail patients spent more days in the hospital (8.2 vs 6.8, P = .02) and incurred more charges across hospital stays ($275,000 vs $188,000, P < .01). Patients >75 years old (OR, 1.26 [1.03-1.55]) and patients with electrolyte abnormalities (OR, 1.25 [1.07-1.46] were significantly more likely to be readmitted. CONCLUSION In this head and neck cancer surgical population, HFRS significantly predicted unplanned readmission. HFRS is a potential risk stratification tool and should be compared with other methods and explored in other cancer populations. Beyond the challenge of identifying at-risk patients, future work should explore potential interventions aimed at mitigating readmission.
Collapse
Affiliation(s)
- Rohith S Voora
- School of Medicine, University of California-San Diego, San Diego, California, USA.,Division of Otolaryngology-Head and Neck Surgery, University of California-San Diego, San Diego, California, USA
| | - Alexander S Qian
- School of Medicine, University of California-San Diego, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California-San Diego, La Jolla, California, USA
| | - Nikhil V Kotha
- School of Medicine, University of California-San Diego, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California-San Diego, La Jolla, California, USA
| | - Edmund M Qiao
- School of Medicine, University of California-San Diego, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California-San Diego, La Jolla, California, USA
| | - Minhthy Meineke
- Department of Anesthesiology, School of Medicine, University of California-San Diego, La Jolla, California, USA
| | - James D Murphy
- Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California-San Diego, La Jolla, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Ryan K Orosco
- Division of Otolaryngology-Head and Neck Surgery, University of California-San Diego, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA
| |
Collapse
|
5
|
Qiao EM, Guram K, Kotha NV, Voora RS, Qian A, Ahn GS, Kalavacherla S, Pindus R, Stewart TF, Banegas MP, Murphy JD, Rose BS. Increasing primary care utilization prior to cancer diagnosis in association with cancer mortality. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.10548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10548 Background: Primary care physicians (PCPs) are significant contributors of early cancer detection yet few studies have investigated whether consistent primary care translates to improved downstream outcomes. We evaluated the impact of prior PCP utilization on metastatic disease at diagnosis and cancer-specific mortality (CSM) for a general cancer cohort and 12 tumor subtypes. Methods: We identified cancer patients ≥40 years, diagnosed from 2004-2017 within the Veterans Health Administration. For our 5-year pre-diagnostic period, we binned PCP visits into none (0 visits), some (1-4), and annual (5). Multivariable logistic regression assessed the effect of PCP utilization on metastatic disease at diagnosis and Fine-Gray regression with non-cancer death as a competing event evaluated their effect on cancer-specific mortality (CSM). These were repeated for each subtype. Results: Among 245,425 patients, mean age was 66 years with 5.7-year median follow-up. Compared with 0 visits, some PCP utilization was associated with 26% reduced odds of metastatic disease at diagnosis (odds ratio (OR), 95% confidence interval (CI): 0.74 [0.71-0.76] P<0.01) and 12% lower risk of CSM (hazard ratio (HR), 95% CI: 0.88 [0.86-0.89] P<0.01). Annual PCP utilization was associated with 39% reduced odds of metastatic disease (OR, 95% CI: 0.61 [0.59-0.63] P<0.01) and 21% lower risk of CSM (HR, 95% CI: 0.79 [0.77-0.81] P<0.01). Among subtypes, prostate cancer had the largest effect size for PCP utilization on metastatic disease at diagnosis (ORannual, 95% CI: 0.32 [0.30-0.35] P<0.01) and CSM (HRannual, 95% CI: 0.51 [0.48-0.55] P<0.01). Pancreas cancer had the lowest effect size on metastatic disease at diagnosis (ORannual, 95% CI: 0.87 [0.73-1.04] P: 0.12) and CSM (HRannual, 95% CI: 0.89 [0.82-0.97] P<0.01). The table displays additional subtypes. Conclusions: Increased PCP utilization prior to cancer diagnosis is associated with a significant decrease in metastatic disease at diagnosis and CSM, with annual utilization associated with the greatest decrease. These results are consistent when stratifying by tumor subtype. Consistent primary care must be emphasized for patients at risk of cancer. [Table: see text]
Collapse
Affiliation(s)
- Edmund Men Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Kripa Guram
- VA San Diego Healthcare System, San Diego, CA
| | - Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | - Alexander Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | - Sandhya Kalavacherla
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Ramona Pindus
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | | | - James Don Murphy
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Brent S. Rose
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| |
Collapse
|
6
|
Qiao EM, Qian AS, Nalawade V, Voora RS, Kotha NV, Vitzthum LK, Murphy JD. Evaluating High-Dimensional Machine Learning Models to Predict Hospital Mortality Among Older Patients With Cancer. JCO Clin Cancer Inform 2022; 6:e2100186. [PMID: 35671416 DOI: 10.1200/cci.21.00186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Older hospitalized cancer patients face high risks of hospital mortality. Improved risk stratification could help identify high-risk patients who may benefit from future interventions, although we lack validated tools to predict in-hospital mortality for patients with cancer. We evaluated the ability of a high-dimensional machine learning prediction model to predict inpatient mortality and compared the performance of this model to existing prediction indices. METHODS We identified patients with cancer older than 75 years from the National Emergency Department Sample between 2016 and 2018. We constructed a high-dimensional predictive model called Cancer Frailty Assessment Tool (cFAST), which used an extreme gradient boosting algorithm to predict in-hospital mortality. cFAST model inputs included patient demographic, hospital variables, and diagnosis codes. Model performance was assessed with an area under the curve (AUC) from receiver operating characteristic curves, with an AUC of 1.0 indicating perfect prediction. We compared model performance to existing indices including the Modified 5-Item Frailty Index, Charlson comorbidity index, and Hospital Frailty Risk Score. RESULTS We identified 2,723,330 weighted emergency department visits among older patients with cancer, of whom 144,653 (5.3%) died in the hospital. Our cFAST model included 240 features and demonstrated an AUC of 0.92. Comparator models including the Modified 5-Item Frailty Index, Charlson comorbidity index, and Hospital Frailty Risk Score achieved AUCs of 0.58, 0.62, and 0.71, respectively. Predictive features of the cFAST model included acute conditions (respiratory failure and shock), chronic conditions (lipidemia and hypertension), patient demographics (age and sex), and cancer and treatment characteristics (metastasis and palliative care). CONCLUSION High-dimensional machine learning models enabled accurate prediction of in-hospital mortality among older patients with cancer, outperforming existing prediction indices. These models show promise in identifying patients at risk of severe adverse outcomes, although additional validation and research studying clinical implementation of these tools is needed.
Collapse
Affiliation(s)
- Edmund M Qiao
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA
| | - Alexander S Qian
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA
| | - Rohith S Voora
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA
| | - Nikhil V Kotha
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA
| | - Lucas K Vitzthum
- Department of Radiation Oncology, Stanford University, Stanford, CA
| | - James D Murphy
- Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA
| |
Collapse
|
7
|
Kotha NV, Kumar A, Nelson TJ, Qiao EM, Qian AS, Voora RS, McKay RR, Rose BS, Stewart TF. Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer. Urol Oncol 2022; 40:274.e1-274.e6. [PMID: 35216893 PMCID: PMC8863428 DOI: 10.1016/j.urolonc.2022.01.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 12/22/2021] [Accepted: 01/15/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about delaying treatment for localized cancer and its impact on long-term outcomes. OBJECTIVE We aimed to investigate the impact of time to chemoradiation (CRT) on recurrence and survival outcomes for patients with muscle-invasive bladder cancer (MIBC). METHODS In the national Veterans Affairs' database, we identified patients with urothelial histology, MIBC (T2-4a/N0-3/M0) diagnosed between 2000 to 2018 and treated with definitive CRT. Time to treatment was defined as the number of days between date of diagnosis and start date of CRT. The cohort was stratified into < 90 (early) or ≥ 90 days (delayed) groups. Endpoints of locoregional failure (LRF), distant failure (DF), overall survival (OS), and bladder cancer-specific survival (BCS) were evaluated in multivariable Cox and Fine-Gray models. RESULTS 305 patients with MIBC underwent CRT - 190 (62.3%) received early CRT, 115 (37.7%) received delayed CRT. Multivariable analysis (including success of transurethral resection of bladder tumor and type of chemotherapy) revealed no difference in recurrence between groups - LRF HR 1.12 (95%CI 0.76-1.67, P = 0.56) and DF HR 1.03 (95%CI 0.70-1.53, P = 0.88). Similarly, there were no differences in survival outcomes. The lack of association was maintained at both earlier and later time cutoffs (60-120 days). CONCLUSIONS Our findings suggest that a short-term delay in definitive therapy may not affect long-term outcomes for patients with MIBC undergoing CRT. This study does not endorse delays in therapy, but rather provides information to aid patients and clinicians navigate the unique challenges of MIBC care in both pandemic and non-pandemic times.
Collapse
Affiliation(s)
- Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA,Veterans Affairs San Diego Healthcare System, San Diego, CA
| | - Abhishek Kumar
- Veterans Affairs San Diego Healthcare System, San Diego, CA,Department of Radiation Oncology, Duke University, Durham, NC
| | - Tyler J. Nelson
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA,Veterans Affairs San Diego Healthcare System, San Diego, CA
| | - Edmund M. Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA,Veterans Affairs San Diego Healthcare System, San Diego, CA
| | - Alex S. Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA,Veterans Affairs San Diego Healthcare System, San Diego, CA
| | - Rohith S. Voora
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA,Veterans Affairs San Diego Healthcare System, San Diego, CA
| | - Rana R. McKay
- Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, CA
| | - Brent S. Rose
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA,Veterans Affairs San Diego Healthcare System, San Diego, CA
| | - Tyler F. Stewart
- Veterans Affairs San Diego Healthcare System, San Diego, CA,Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, CA,Corresponding author: Ph: 858-822-6185, Fax: 858-249-0905
| |
Collapse
|
8
|
Kotha NV, Kumar A, Qiao EM, Qian AS, Voora RS, Nalawade V, Karim Kader A, McKay RR, Stewart TF, Rose BS. Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer. J Natl Cancer Inst 2021; 114:600-608. [PMID: 34918091 PMCID: PMC9002275 DOI: 10.1093/jnci/djab219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 09/17/2021] [Accepted: 11/29/2021] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND African American patients with bladder cancer have inferior outcomes compared with non-Hispanic White (White) patients. We hypothesize that access to health care is a primary determinant of this disparity. We compared outcomes by race for patients with bladder cancer receiving care within the predominant hybrid-payer health-care model of the United States captured in the Surveillance, Epidemiology, and End Results (SEER) database with those receiving care within the equal-access model of the Veterans' Health Administration (VHA). METHODS African American and White patients diagnosed with bladder cancer were identified in SEER and VHA. Stage at presentation, bladder cancer-specific mortality (BCM), and overall survival (OS) were compared by race within each health-care system. RESULTS The SEER cohort included 122 449 patients (93.7% White, 6.3% African American). The VHA cohort included 36 322 patients (91.0% White, 9.0% African American). In both cohorts, African American patients were more likely to present with muscle-invasive disease and metastases, but the differences between races were statistically significantly smaller in VHA. In SEER multivariable models, African American patients had worse BCM (hazard ratio [HR] = 1.22, 95% confidence interval [CI] = 1.15 to 1.29) and OS (HR = 1.26, 95% CI = 1.20 to 1.31). In contrast within the VHA, African American patients had similar BCM (HR = 0.97, 95% CI = 0.88 to 1.07) and OS (HR = 0.99, 95% CI = 0.93 to 1.05). CONCLUSIONS In this study of contrasting health-care models, receiving medical care in an equal-access system was associated with reduced differences in stage at presentation and eliminated disparities in survival outcomes for African American patients with bladder cancer. Our findings highlight the importance of reducing financial barriers to care to notably improve health equity and oncologic outcomes for African American patients.
Collapse
Affiliation(s)
- Nikhil V Kotha
- School of Medicine, University of California San Diego, La Jolla, CA, USA,Veterans Affairs San Diego Healthcare System, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Abhishek Kumar
- Veterans Affairs San Diego Healthcare System, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Edmund M Qiao
- School of Medicine, University of California San Diego, La Jolla, CA, USA,Veterans Affairs San Diego Healthcare System, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Alex S Qian
- School of Medicine, University of California San Diego, La Jolla, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Rohith S Voora
- School of Medicine, University of California San Diego, La Jolla, CA, USA,Veterans Affairs San Diego Healthcare System, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Vinit Nalawade
- Veterans Affairs San Diego Healthcare System, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - A Karim Kader
- Department of Urology, University of California San Diego, La Jolla, CA, USA
| | - Rana R McKay
- Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Tyler F Stewart
- Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Brent S Rose
- Correspondence to: Brent S. Rose, MD, Department of Radiation Medicine and Applied Sciences, Altman Clinical and Translational Research Institute, University of California San Diego, 9452 Medical Center Dr, La Jolla, CA 92037, USA (e-mail: )
| |
Collapse
|
9
|
Qiao EM, Lynch JA, Lee KM, Kotha NV, Nalawade V, Voora RS, Qian AS, Nelson TJ, Yamoah K, Garraway IP, Stewart TF, Parsons JK, Rose BS. Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer. J Natl Cancer Inst 2021; 114:592-599. [PMID: 34893859 PMCID: PMC9002290 DOI: 10.1093/jnci/djab221] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 08/02/2021] [Accepted: 11/30/2021] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Despite higher risks associated with prostate cancer, young African American men are poorly represented in prostate-specific antigen (PSA) trials, which limits proper evidence-based guidance. We evaluated the impact of PSA screening, alongside primary care provider utilization, on prostate cancer outcomes for these patients. METHODS We identified African American men aged 40-55 years, diagnosed with prostate cancer between 2004 and 2017 within the Veterans Health Administration. Inverse probability of treatment-weighted propensity scores were used in multivariable models to assess PSA screening on PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis. Lead-time adjusted Fine-Gray regression evaluated PSA screening on prostate cancer-specific mortality (PCSM), with noncancer death as competing events. All statistical tests were 2-sided. RESULTS The cohort included 4726 patients. Mean age was 51.8 years, with 84-month median follow-up. There were 1057 (22.4%) with no PSA screening prior to diagnosis. Compared with no screening, PSA screening was associated with statistically significantly reduced odds of PSA levels higher than 20 (odds ratio [OR] = 0.56, 95% confidence interval [CI] = 0.49 to 0.63; P < .001), Gleason score of 8 or higher (OR = 0.78, 95% CI = 0.69 to 0.88; P < .001), and metastatic disease at diagnosis (OR = 0.50, 95% CI = 0.39 to 0.64; P < .001), and decreased PCSM (subdistribution hazard ratio = 0.52, 95% CI = 0.36 to 0.76; P < .001). Primary care provider visits displayed similar effects. CONCLUSIONS Among young African American men diagnosed with prostate cancer, PSA screening was associated with statistically significantly lower risk of PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis and statistically significantly reduced risk of PCSM. However, the retrospective design limits precise estimation of screening effects. Prospective studies are needed to validate these findings.
Collapse
Affiliation(s)
- Edmund M Qiao
- Veterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA
| | - Julie A Lynch
- Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA
| | - Kyung M Lee
- Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA
| | - Nikhil V Kotha
- Veterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA
| | - Vinit Nalawade
- Veterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA
| | - Rohith S Voora
- Veterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA
| | - Alexander S Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA
| | - Tyler J Nelson
- Veterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA
| | - Kosj Yamoah
- Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| | - Isla P Garraway
- Department of Urology, University of California Los Angeles, Los Angeles, CA, USA
| | - Tyler F Stewart
- Division of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, CA, USA
| | - J Kellogg Parsons
- Department of Urology, University of California San Diego, La Jolla, San Diego, CA, USA
| | - Brent S Rose
- Correspondence to: Brent S. Rose, MD, Department of Radiation Medicine and Applied Sciences, University of California, 3960 Health Sciences Drive, La Jolla, San Diego, CA 92093-0865, USA (e-mail: )
| |
Collapse
|
10
|
Voora RS, Carvalho D, Jiang W. Impact of Tonsillectomy on Obesity in Pediatric Patients With Sleep-Disordered Breathing. OTO Open 2021; 5:2473974X211059105. [PMID: 34870061 PMCID: PMC8637722 DOI: 10.1177/2473974x211059105] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 10/15/2021] [Indexed: 11/16/2022] Open
Abstract
Objective Both tonsillar hypertrophy and obesity contribute to pediatric
sleep-disordered breathing (SDB). Tonsillectomy addresses anatomical
obstruction causing SDB; however, it may adversely affect the obesity
profile postoperatively. Herein, we investigate posttonsillectomy body mass
index (BMI) changes in pediatric patients. Study Design Retrospective case series. Setting Tertiary, pediatric urban academic center. Methods All patients undergoing tonsillectomy from January 1, 2016, to December 31,
2016, were included. Patients’ age, sex, surgical indication, and
preoperative BMI were recorded. Postoperative BMI data were collected
between March 1, 2016, and December 31, 2017. Statistical analysis was
performed using a generalized regression model, using BMI percentile-for-age
weight status. Results A total of 1153 patients were included (50% female), with age ranging from
2.0 to 19.5 years (mean [SD], 7.6 [4.0]). The majority (87.8%) had
tonsillectomy for SDB. Of the cohort, 560 (48.6%) had available follow-up
BMI data. The BMI percentile on the day of the surgery had a median of 65.8,
and the BMI percentile on follow-up had a median of 76.4. The median time to
follow-up was 197 days with a range of 50 to 605 days. Higher postoperative
BMI percentile strongly correlated to higher preoperative BMI percentile
(P < .001), as well as younger age
(P < .001), male sex (P = .0005),
and SDB as a surgical indication (P = .003). Conclusion We observed a significant increase in BMI percentile following tonsillectomy,
which accounted for a significantly higher proportion of the cohort being
classified as overweight or obese postoperatively. These findings
necessitate greater preoperative counseling, closer follow-up, and
adjunctive measures for obesity management in pediatric patients undergoing
tonsillectomy.
Collapse
Affiliation(s)
- Rohith S Voora
- School of Medicine, University of California, San Diego, San Diego, California, USA.,Pediatric Otolaryngology, Rady Children's Hospital San Diego, San Diego, California, USA
| | - Daniela Carvalho
- Pediatric Otolaryngology, Rady Children's Hospital San Diego, San Diego, California, USA.,Department of Otolaryngology, University of California, San Diego, San Diego, California, USA
| | - Wen Jiang
- Pediatric Otolaryngology, Rady Children's Hospital San Diego, San Diego, California, USA.,Department of Otolaryngology, University of California, San Diego, San Diego, California, USA
| |
Collapse
|
11
|
Said M, Voora RS, Hom DB. Is a Tooth Extraction Required If Dentition Lies Within a Mandible Fracture? Laryngoscope 2021; 132:1701-1703. [PMID: 34846067 DOI: 10.1002/lary.29962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 11/15/2021] [Accepted: 11/17/2021] [Indexed: 11/10/2022]
Affiliation(s)
- Mena Said
- Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Diego, San Diego, California, U.S.A
| | - Rohith S Voora
- Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Diego, San Diego, California, U.S.A
| | - David B Hom
- Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Diego, San Diego, California, U.S.A
| |
Collapse
|
12
|
Qian AS, Qiao EM, Nalawade V, Voora RS, Kotha NV, Dameff C, Coyne CJ, Murphy JD. Impact of underlying malignancy on emergency department utilization and outcomes. Cancer Med 2021; 10:9129-9138. [PMID: 34821051 PMCID: PMC8683529 DOI: 10.1002/cam4.4414] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 10/14/2021] [Accepted: 10/24/2021] [Indexed: 11/11/2022] Open
Abstract
PURPOSE Cancer patients frequently utilize the emergency department (ED) for a variety of diagnoses both related to and unrelated to their cancer, yet ED outcomes for cancer patients are not well documented. This study sought to define risks and identify predictors for inpatient admission and hospital mortality among cancer patients presenting to the ED. PATIENTS AND METHODS We utilized the National Emergency Department Sample to identify patients with and without a diagnosis of cancer presenting to the ED between January 2016 and December 2018. We used multivariable mixed-effects logistic regression models to assess the influence of cancer on outcomes of hospital admission after the ED visit and hospital mortality for the whole patient cohort and individual presenting diagnoses. RESULTS There were 340 million weighted ED visits, of which 8.3 million (2.3%) were associated with a cancer diagnosis. Compared to non-cancer patients, patients with cancer had an increased risk of inpatient admission (64.7% vs. 14.8%; p < 0.0001) and hospital mortality (4.6% vs. 0.5%; p < 0.0001). For each of the top 15 presenting diagnoses, cancer patients had increased risks of hospitalization (odds ratio [OR] range 2.0-13.2) or death (OR range 2.1-14.4). Although our dataset does not contain reliable estimation of stage, cancer site was the most robust individual predictor associated with the risk of hospitalization or death compared to other clinical or system-related factors. CONCLUSIONS Cancer patients in the ED have high risks for hospital admission and death when compared to patients without cancer. Cancer patients represent a distinct population and may benefit from cancer-specific risk stratification or focused interventions to improve outcomes.
Collapse
Affiliation(s)
- Alexander S Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA
| | - Edmund M Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA
| | - Rohith S Voora
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA
| | - Nikhil V Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA
| | - Christian Dameff
- Department of Emergency Medicine, University of California San Diego, La Jolla, California, USA
| | - Christopher J Coyne
- Department of Emergency Medicine, University of California San Diego, La Jolla, California, USA
| | - James D Murphy
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA
| |
Collapse
|
13
|
Kotha NV, Kumar A, Nelson TJ, Qiao EM, Qian AS, Voora RS, McKay RR, Stewart TF, Rose BS. Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation. Adv Radiat Oncol 2021; 7:100836. [PMID: 35071834 PMCID: PMC8767252 DOI: 10.1016/j.adro.2021.100836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Accepted: 10/11/2021] [Indexed: 11/16/2022] Open
Abstract
PURPOSE Chemoradiation (CRT) is a definitive treatment option for muscle-invasive bladder cancer (MIBC). Despite its effectiveness, CRT is underused, in part owing to concerns of tolerability and the need for integrated multidisciplinary care. We investigated factors associated with and the impact of treatment discontinuation in patients with MIBC treated with CRT. METHODS AND MATERIALS In the US Veterans Affairs' national database, we identified patients with urothelial histology, MIBC (T2-4a/N0-3/M0) diagnosed between 2000 and 2018 and treated with definitive-intent CRT. The primary endpoint of discontinued radiation was evaluated in a multivariable logistic regression. Secondary endpoints of 30-day and 90-day mortality, overall mortality, and nonbladder cancer mortality were evaluated in multivariable models. RESULTS Of 369 veterans with MIBC who underwent CRT, 30 patients (8.1%) did not complete radiation. The most common reasons for treatment discontinuation included comorbidities or infections necessitating hospital admission (63.3%) and treatment intolerance or declining performance status (26.7%). In multivariable logistic regression, variables associated with radiation discontinuation were creatinine clearance ≤ 50 (odds ratio [OR], 3.93; 95% CI, 1.63-9.50; P = .002), incomplete transurethral resection of bladder tumor (TURBT) (OR, 3.16; 95% CI, 1.15-8.63; P = .02), and nonpreferred chemotherapy (OR, 3.31; 95% CI, 1.31-8.36; P = .01). In the cohort that discontinued radiation, 30-day mortality was 33.3% and 90-day mortality was 50.0%, with the majority of deaths attributed to nonbladder cancer causes. No patient or tumor variables were associated with either endpoint. In the cohort that completed radiation, 30-day mortality was 2.7% and 90-day mortality was 6.8%. In multivariable analysis, radiation discontinuation was associated with worse overall mortality (hazard ratio [HR], 2.48; 95% CI, 1.36-4.50; P = .003) and worse nonbladder cancer mortality (HR, 2.32; 95% CI, 1.24-4.34; P = .008). CONCLUSIONS With a low rate of treatment discontinuation, CRT is an effective and feasible treatment option for the typically elderly and comorbid population of patients with MIBC. In addition to identified predictors of treatment discontinuation (poor renal function, incomplete TURBT, etc.), further research is required to develop evidence-based guidelines for optimal patient selection.
Collapse
Affiliation(s)
- Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California,Veterans Affairs San Diego Healthcare System, San Diego, California,Corresponding author: Nikhil V. Kotha, BS
| | - Abhishek Kumar
- Veterans Affairs San Diego Healthcare System, San Diego, California,Department of Radiation Oncology, Duke University, Durham, North Carolina
| | - Tyler J. Nelson
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California,Veterans Affairs San Diego Healthcare System, San Diego, California
| | - Edmund M. Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California,Veterans Affairs San Diego Healthcare System, San Diego, California
| | - Alex S. Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California,Veterans Affairs San Diego Healthcare System, San Diego, California
| | - Rohith S. Voora
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California,Veterans Affairs San Diego Healthcare System, San Diego, California
| | - Rana R. McKay
- Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, California
| | - Tyler F. Stewart
- Veterans Affairs San Diego Healthcare System, San Diego, California,Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, California
| | - Brent S. Rose
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California,Veterans Affairs San Diego Healthcare System, San Diego, California
| |
Collapse
|
14
|
Kotha NV, Voora RS, Qian AS, Kumar A, Qiao EM, Stewart TF, Rose BS, Orosco RK. Prognostic Utility of Pretreatment Neutrophil-Lymphocyte Ratio in Advanced Larynx Cancer. Biomark Insights 2021; 16:11772719211049848. [PMID: 34658619 PMCID: PMC8512256 DOI: 10.1177/11772719211049848] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2021] [Accepted: 09/03/2021] [Indexed: 12/11/2022] Open
Abstract
Purpose: Neutrophil-lymphocyte ratio has been explored as a prognosticator in several
cancer types, but its association with larynx cancer outcomes is not well
known. We aimed to identify an optimal NLR cutoff point and examine the
prognostic utility of this biomarker in patients with locoregionally
advanced larynx cancer treated with curative intent. Methods: In the Veterans Affairs’ (VA) national database, we identified patients with
locoregionally advanced (T3-4N0-3M0) laryngeal squamous cell carcinoma
diagnosed between 2000 and 2017 and treated with curative intent. NLR cutoff
points were calculated using Contal/O’Quigley’s method. Outcomes of larynx
cancer-specific survival (CSS), overall survival (OS), and non-larynx cancer
survival (NCS) were evaluated in multivariable Cox and Fine-Gray models. Results: In 1047 patients, the optimal pretreatment NLR cutoff was identified as 4.17
- 722 patients with NLR ⩽ 4.17, 325 patients with NLR > 4.17. The
elevated NLR cohort had a higher proportion of T4 disease (39.4% vs 28.4%),
node positive disease (52.3% vs 43.1%), and surgical treatment (43.7% vs
35.2%). In multivariable analysis, NLR > 4.17 was independently
associated with worse OS (HR 1.31, 95% CI 1.12-1.54,
P = .001) and worse CSS (HR 1.46, 95% CI 1.17-1.83,
P < .001), but not with NCS (HR 0.94, 95% CI
0.75-1.18, P = .58). Conclusion: In locoregionally advanced larynx cancer treated with curative intent, we
identified elevated NLR to be associated with inferior OS and CSS. Further
prospective studies are needed to investigate pretreatment NLR and our
identified 4.17 cutoff as a potential larynx cancer-specific marker for this
high risk population.
Collapse
Affiliation(s)
- Nikhil V Kotha
- School of Medicine, University of California San Diego, La Jolla, CA, USA.,Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Rohith S Voora
- School of Medicine, University of California San Diego, La Jolla, CA, USA.,Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.,Division of Otolaryngology-Head & Neck Surgery, University of California San Diego, La Jolla, CA, USA
| | - Alex S Qian
- School of Medicine, University of California San Diego, La Jolla, CA, USA.,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Abhishek Kumar
- Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.,Department of Radiation Oncology, Duke University, Durham, NC, USA
| | - Edmund M Qiao
- School of Medicine, University of California San Diego, La Jolla, CA, USA.,Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
| | - Tyler F Stewart
- Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.,Moores Cancer Center at University of California San Diego Health, La Jolla, CA, USA
| | - Brent S Rose
- Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.,Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.,Moores Cancer Center at University of California San Diego Health, La Jolla, CA, USA
| | - Ryan K Orosco
- Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.,Division of Otolaryngology-Head & Neck Surgery, University of California San Diego, La Jolla, CA, USA.,Moores Cancer Center at University of California San Diego Health, La Jolla, CA, USA
| |
Collapse
|
15
|
Voora RS, Panuganti BA, Flagg M, Nelson T, Kotha NV, Qiao EM, Qian AS, Kumar A, Stewart TF, Rose B, Califano J, Weissbrod PA, Mell LK, Orosco RK. Patterns of Failure After Definitive Treatment of T4a Larynx Cancer. Otolaryngol Head Neck Surg 2021; 167:274-285. [PMID: 34609937 DOI: 10.1177/01945998211049211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE Recurrence is known to predict laryngeal squamous cell cancer (LSCC) survival. Recurrence patterns in T4a LSCC are poorly characterized and represent a possible explanation for observed survival discrepancies by treatment rendered. STUDY DESIGN Retrospective database review. SETTING Veterans Affairs national database. METHODS Patients with T4a LSCC between 2000 and 2017 were identified and stratified by treatment (chemoradiotherapy [CRT] vs total laryngectomy + neck dissection + adjuvant therapy [surgical]). Primary outcomes were locoregional and distant recurrence. Secondary outcomes of overall mortality, larynx cancer mortality, and noncancer mortality were evaluated in Cox and Fine-Gray models. RESULTS A total of 1043 patients had comparable baseline demographics: 438 in the CRT group and 605 in the surgical group. Patients undergoing CRT had higher proportions of node positivity (64.6% vs 53.1%, P < .001). Locoregional and distant recurrence were less common in the surgical group (23.0% vs 37.2%, P < .001; 6.8% vs 13.3%, P < .001, respectively); however, distant metastatic rates did not differ within the N0 subgroup (P = .722). On multivariable regression, surgery demonstrated favorable locoregional recurrence (hazard ratio [HR], 0.49; 95% CI, 0.39-0.62; P < .001), distant recurrence (HR, 0.47; 95% CI, 0.31-0.71; P < .001), overall mortality (HR, 0.75; 95% CI, 0.64-0.87; P < .001), and larynx cancer mortality (HR, 0.69; 95% CI, 0.56-0.85; P < .001). CONCLUSION T4a LSCC survival discrepancies between surgical and nonsurgical treatment are influenced by varying recurrence behaviors. Surgery was associated with superior disease control and improved survival. Beyond the known benefit in locoregional control with surgery, there may be a protective effect on distant recurrence that depends on regional disease burden.
Collapse
Affiliation(s)
- Rohith S Voora
- School of Medicine, University of California San Diego, San Diego, California, USA.,Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California, USA.,Veterans Affairs San Diego Healthcare System, San Diego, California, USA
| | - Bharat A Panuganti
- Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Mitchell Flagg
- School of Medicine, University of California San Diego, San Diego, California, USA.,Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California, USA
| | - Tyler Nelson
- School of Medicine, University of California San Diego, San Diego, California, USA.,Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California San Diego, La Jolla, California, USA
| | - Nikhil V Kotha
- School of Medicine, University of California San Diego, San Diego, California, USA.,Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California San Diego, La Jolla, California, USA
| | - Edmund M Qiao
- School of Medicine, University of California San Diego, San Diego, California, USA.,Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California San Diego, La Jolla, California, USA
| | - Alexander S Qian
- School of Medicine, University of California San Diego, San Diego, California, USA.,Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California San Diego, La Jolla, California, USA
| | - Abhishek Kumar
- Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California San Diego, La Jolla, California, USA
| | - Tyler F Stewart
- Moores Cancer Center, La Jolla, California, USA.,Divisions of Hematology-Oncology and Blood and Marrow Transplantation, University of California San Diego, San Diego, California, USA
| | - Brent Rose
- Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California San Diego, La Jolla, California, USA
| | - Joseph Califano
- Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California, USA.,Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Philip A Weissbrod
- Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Loren K Mell
- Moores Cancer Center, La Jolla, California, USA.,Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California San Diego, La Jolla, California, USA
| | - Ryan K Orosco
- Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California, USA.,Veterans Affairs San Diego Healthcare System, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA
| |
Collapse
|
16
|
Qiao EM, Voora RS, Nalawade V, Kotha NV, Qian AS, Nelson TJ, Durkin M, Vitzthum LK, Murphy JD, Stewart TF, Rose BS. Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients. Cancer Med 2021; 10:7289-7297. [PMID: 34528761 PMCID: PMC8525167 DOI: 10.1002/cam4.4229] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 07/30/2021] [Accepted: 07/31/2021] [Indexed: 12/19/2022] Open
Abstract
Background Despite guideline recommendations, utilization of low‐dose computed tomography (LDCT) for lung cancer screening remains low. The driving factors behind these low rates and the real‐world effect of LDCT utilization on lung cancer outcomes remain limited. Methods We identified patients diagnosed with non‐small cell lung cancer (NSCLC) from 2015 to 2017 within the Veterans Health Administration. Multivariable logistic regression assessed the influence of LDCT screening on stage at diagnosis. Lead time correction using published LDCT lead times was performed. Cancer‐specific mortality (CSM) was evaluated using Fine–Gray regression with non‐cancer death as a competing risk. A lasso machine learning model identified important predictors for receiving LDCT screening. Results Among 4664 patients, mean age was 67.8 with 58‐month median follow‐up, 95% CI = [7–71], and 118 patients received ≥1 screening LDCT before NSCLC diagnosis. From 2015 to 2017, LDCT screening increased (0.1%–6.6%, mean = 1.3%). Compared with no screening, patients with ≥1 LDCT were more than twice as likely to present with stage I disease at diagnosis (odds ratio [OR] 2.16 [95% CI 1.46–3.20]) and less than half as likely to present with stage IV (OR 0.38 [CI 0.21–0.70]). Screened patients had lower risk of CSM even after adjusting for LDCT lead time (subdistribution hazard ratio 0.60 [CI 0.42–0.85]). The machine learning model achieved an area under curve of 0.87 and identified diagnosis year and region as the most important predictors for receiving LDCT. White, non‐Hispanic patients were more likely to receive LDCT screening, whereas minority, older, female, and unemployed patients were less likely. Conclusions Utilization of LDCT screening is increasing, although remains low. Consistent with randomized data, LDCT‐screened patients were diagnosed at earlier stages and had lower CSM. LDCT availability appeared to be the main predictor of utilization. Providing access to more patients, including those in diverse racial and socioeconomic groups, should be a priority.
Collapse
Affiliation(s)
- Edmund M Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| | - Rohith S Voora
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| | - Nikhil V Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| | - Alexander S Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| | - Tyler J Nelson
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| | - Michael Durkin
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA
| | - Lucas K Vitzthum
- Department of Radiation Oncology, Stanford University, Stanford, California, USA
| | - James D Murphy
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| | - Tyler F Stewart
- Division of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, California, USA
| | - Brent S Rose
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.,Veterans Health Administration San Diego Health Care System, La Jolla, California, USA
| |
Collapse
|
17
|
Voora RS, Stramiello JA, Sumner WA, Finegersh A, Mohammadzadeh A, Fouania J, Ramsey C, Blumenfeld L, Sacco AG, Mell LK, Califano JA, Orosco RK. Quality improvement intervention to reduce time to postoperative radiation in head and neck free flap patients. Head Neck 2021; 43:3530-3539. [PMID: 34492135 DOI: 10.1002/hed.26852] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Revised: 07/07/2021] [Accepted: 08/18/2021] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Best-practice guidelines for head and neck cancer patients advise postoperative radiation therapy (PORT) initiation within 6 weeks of surgery. We report our institutional experience improving timeliness of adjuvant radiation in free-flap patients. METHODS Thirty-nine patients met inclusion criteria in the 2017-2019 study period. We divided into "Early" (n = 19) and "Late" (n = 20) time-period groups to compare performance over time. The primary endpoint was time to PORT initiation, with success defined as <6 weeks. RESULTS The number of patients achieving timely PORT improved from 10.5% in the Early group to 50.0% in the Late group (p = 0.014). Patients undergoing concurrent adjuvant chemoradiation were more likely to meet the PORT target in the Late group (p = 0.012). CONCLUSIONS We ascribe this quality improvement in free-flap patients to increased communication among multidisciplinary care teams, proactive consultation referrals, and a targeted patient-navigator intervention. Though work is needed to further improve performance, insight gained from our experience may benefit other teams.
Collapse
Affiliation(s)
- Rohith S Voora
- University of California, San Diego School of Medicine, La Jolla, California, USA.,Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego School of Medicine, La Jolla, California, USA
| | - Joshua A Stramiello
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego School of Medicine, La Jolla, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Whitney A Sumner
- Moores Cancer Center, La Jolla, California, USA.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, USA
| | - Andrey Finegersh
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego School of Medicine, La Jolla, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Amir Mohammadzadeh
- University of California, San Diego School of Medicine, La Jolla, California, USA.,Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego School of Medicine, La Jolla, California, USA
| | | | | | | | - Assuntina G Sacco
- Moores Cancer Center, La Jolla, California, USA.,Division of Hematology-Oncology University, Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA
| | - Loren K Mell
- Moores Cancer Center, La Jolla, California, USA.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, USA
| | - Joseph A Califano
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego School of Medicine, La Jolla, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Ryan K Orosco
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego School of Medicine, La Jolla, California, USA.,Moores Cancer Center, La Jolla, California, USA
| |
Collapse
|
18
|
Finegersh A, Voora RS, Panuganti B, Faraji F, Holsinger FC, Brumund KT, Coffey C, Califano J, Orosco RK. Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study. Oral Oncol 2021; 121:105440. [PMID: 34329867 DOI: 10.1016/j.oraloncology.2021.105440] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Revised: 05/08/2021] [Accepted: 06/30/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Hypopharyngeal cancer is associated with poor survival. Robotic surgery is emerging as a treatment for hypopharyngeal tumors, but no rigorous data are available to assess its effect on survival. METHODS The National Cancer Database (NCDB) was used to identify patients with T1 and T2 hypopharyngeal tumors undergoing robotic surgery, laser surgery, and primary radiation with or without chemotherapy from 2010 to 2016. All adult patients with available staging and no distant metastasis were included. RESULTS We compared 57 patients undergoing robotic surgery, 236 undergoing laser surgery, and 5,742 undergoing primary radiation. Compared to laser surgery, patients undergoing robotic surgery were significantly more likely to have negative margins, neck dissection, lower incomes, and care at an academic center. Rates of robotic surgery also significantly increased from 2010 to 2015. After multivariate regression, robotic surgery was associated with significantly improved overall survival compared to laser surgery and primary radiation. CONCLUSION Robotic surgery improves overall survival for T1 and T2 hypopharyngeal tumors compared to laser surgery and primary radiation in this NCDB cohort. This effect may be mediated by decreased positive margin rates relative to laser surgery. Rates of hypopharyngeal robotic surgery are expected to increase with wider adoption of robotic platforms and may improve overall survival rates for hypopharyngeal cancer.
Collapse
Affiliation(s)
- Andrey Finegersh
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA
| | - Rohith S Voora
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA
| | - Bharat Panuganti
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA
| | - Farhoud Faraji
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA
| | | | - Kevin T Brumund
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA; Division of Otolaryngology, Department of Surgery, VA San Diego Health System, La Jolla, CA, USA; Moores Cancer Center, La Jolla, CA, USA
| | - Charles Coffey
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA; Division of Otolaryngology, Department of Surgery, VA San Diego Health System, La Jolla, CA, USA; Moores Cancer Center, La Jolla, CA, USA
| | - Joseph Califano
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, La Jolla, CA, USA
| | - Ryan K Orosco
- Division of Otolaryngology, Department of Surgery, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, La Jolla, CA, USA.
| |
Collapse
|
19
|
Voora RS, Panuganti B, Flagg M, Kumar A, Qian AS, Kotha NV, Qiao EM, Weissbrod PA, Rose B, Orosco RK. Salvage Following Transoral Laser Microsurgery for Early Glottic Cancer in National Veteran Database. Laryngoscope 2021; 131:2766-2772. [PMID: 34296772 DOI: 10.1002/lary.29740] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 06/07/2021] [Accepted: 06/28/2021] [Indexed: 01/12/2023]
Abstract
OBJECTIVES Transoral laser microsurgery (TLM) is commonly utilized for early glottic cancer and offers favorable oncologic and functional outcomes. However, the survival implications of salvage therapy for recurrent or persistent disease have not been definitively characterized. STUDY DESIGN Retrospective, national database cohort study. METHODS Data were extracted from Veterans Health Affairs (VHA) Informatics and Computing Infrastructure (VINCI) concerning the TLM-based management of T1-T2 glottic squamous cell carcinoma patients between 2000 and 2017. Patients were characterized as either requiring TLM-only, or in cases of persistent or recurrent local disease, TLM plus change in treatment modality (radiotherapy, chemoradiotherapy, or open surgery). Predictors of overall survival (OS), cancer-specific survival (CSS), and salvage-free survival were evaluated via Cox and Fine-Gray models. RESULTS About 553 patients (70.9% T1a, 13.4% T1b, 15.7% T2) were included, with a median follow-up time of 74.5 months. The need for non-TLM salvage increased along with more advanced disease (11.7% T1a, 29.7% T1b, 32.2% T2). Compared to patients with T1a disease, those with T1b and T2 tumors initially treated with TLM had a significantly higher probability of receiving non-TLM salvage (T1b: HR 2.70, 95% CI: 1.61-4.54; T2: HR 3.02, 95% CI: 1.88-4.84). In a multivariable model, receipt of non-TLM salvage was not a significant predictor of either OS (HR = 0.91, 95% CI: 0.62-1.33, P = .624) or CSS (HR 1.21 95% CI 0.51-2.86, P = .667). CONCLUSION The majority of patients with early glottic cancer that are managed with TLM do not require additional salvage therapy. When non-TLM salvage was required, there was no decrement in OS or CSS. LEVEL OF EVIDENCE 4 Laryngoscope, 2021.
Collapse
Affiliation(s)
- Rohith S Voora
- University of California, San Diego School of Medicine, La Jolla, California, U.S.A.,Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California-San Diego, San Diego, California, U.S.A.,Veterans Affairs San Diego Healthcare System, San Diego, California, U.S.A
| | - Bharat Panuganti
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California-San Diego, San Diego, California, U.S.A.,Moores Cancer Center, La Jolla, California, U.S.A
| | - Mitchell Flagg
- University of California, San Diego School of Medicine, La Jolla, California, U.S.A.,Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California-San Diego, San Diego, California, U.S.A
| | - Abhishek Kumar
- Veterans Affairs San Diego Healthcare System, San Diego, California, U.S.A.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, U.S.A
| | - Alexander S Qian
- University of California, San Diego School of Medicine, La Jolla, California, U.S.A.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, U.S.A
| | - Nikhil V Kotha
- University of California, San Diego School of Medicine, La Jolla, California, U.S.A.,Veterans Affairs San Diego Healthcare System, San Diego, California, U.S.A.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, U.S.A
| | - Edmund M Qiao
- University of California, San Diego School of Medicine, La Jolla, California, U.S.A.,Veterans Affairs San Diego Healthcare System, San Diego, California, U.S.A.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, U.S.A
| | - Philip A Weissbrod
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California-San Diego, San Diego, California, U.S.A.,Moores Cancer Center, La Jolla, California, U.S.A
| | - Brent Rose
- Veterans Affairs San Diego Healthcare System, San Diego, California, U.S.A.,Moores Cancer Center, La Jolla, California, U.S.A.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, U.S.A
| | - Ryan K Orosco
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California-San Diego, San Diego, California, U.S.A.,Veterans Affairs San Diego Healthcare System, San Diego, California, U.S.A.,Moores Cancer Center, La Jolla, California, U.S.A
| |
Collapse
|
20
|
Lee TC, Qiao EM, Qian AS, Nalawade V, Voora RS, Kotha NV, Dameff C, Coyne CJ, Murphy JD. Predictors of inpatient admission for pediatric cancer patients visiting the emergency department. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e22019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22019 Background: Pediatric cancer patients represent a vulnerable cohort at risk of adverse outcomes after presenting to the emergency department (ED). Given the severity of cancer-related complications and uniqueness of this population, approaches to better risk stratify this cohort could potentially help define future interventions geared towards improving outcomes. We used a high-dimensional machine learning approach to help define the risk of hospitalization after an ED visit among pediatric patients with cancer. Methods: A cohort of cancer patients under 18 was identified from the Nationwide Emergency Department Sample (NEDS) between 2016-2018. We used a lasso regression model to predict inpatient admission after an ED visit. Model covariates included patient demographics, hospital characteristics, and International Classification of Diseases, version 10 (ICD-10) diagnosis codes. The data were split 75%/25% into training/testing data. The model was constructed with training data, and performance assessed on the test data using the area under the curve (AUC), with an AUC of 1.0 indicating perfect prediction. Results: We identified 129,631 pediatric cancer patients who visited the ED, of which 54.5% were subsequently admitted. The final predictive model included 150 variables, including 9 demographic, 6 hospital, and 135 unique ICD-10 codes. The model demonstrated excellent ability to predict hospitalization with an AUC of 0.96. The top 5 most important variables associated with inpatient admission were diagnoses of paralytic ileus/intestinal obstruction, neutropenia, sepsis, aplastic anemia/bone marrow failure, and bacterial infection. Conclusions: Pediatric cancer patients frequently present to the ED with complications of their cancer or their treatment, and over half of these patients are admitted. This study demonstrates the capacity of high-dimensional prediction models to help identify pediatric patients at risk of hospitalization. Additional research is needed to determine how to implement these predictive models in clinical practice.
Collapse
Affiliation(s)
- Terrence C. Lee
- Department of Emergency Medicine, University of California, San Diego, La Jolla, CA
| | - Edmund M. Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Alexander S. Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | - Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Christian Dameff
- Department of Emergency Medicine, University of California, San Diego, La Jolla, CA
| | | | - James Don Murphy
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| |
Collapse
|
21
|
Voora RS, Panuganti B, Flagg M, Kumar A, Kotha NV, Qiao EM, Qian AS, Nelson TJ, Weissbrod PA, Stewart TF, Rose BS, Mell LK, Califano JA, Orosco RK. Patterns of failure after definitive treatment for T4a larynx cancer in the Veterans Affairs Health System. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e18006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18006 Background: Both chemoradiotherapy (CRT) and total laryngectomy (TL) with adjuvant therapy are curative-intent treatment options for patients with T4a larynx cancer. Disease recurrence is a known negative prognosicator, but differences in recurrence patterns and the subsequent survival associations are not well characterized. To address this knowledge gap, we present long-term recurrence and survival outcomes from a novel longitudinal data source. Methods: Retrospective study of non-metastatic T4a larynx cancer patients diagnosed between 2000-2017 who underwent curative-intent treatment (TL with adjuvant therapy or primary CRT) from the VA Informatics and Computing Infrastructure database. Adjuvant therapy consisted of either postoperative radiotherapy (RT) or CRT. Fine-Gray and Cox models were used to evaluate primary outcomes – time to locoregional recurrence and distant recurrence. Secondary outcomes included overall survival (OS), cancer-specific survival (CSS), non-cancer specific survival (NCSS), and disease-free survival (DFS). These multivariable models accounted for age, race, alcohol history, smoking status, education and income, Charlson-Deyo score, N-classification, and tumor subsite. Results: The study included 1,114 patients with a median follow-up time of 63.3 months among those alive at last follow up. In the TL group, adjuvant RT was used in 69% and adjuvant CRT was used in 31%. Median time to first recurrence was 24.4 months with overall incidence of 28.5% locoregional and 9.5% distant recurrence. Primary CRT patients had higher rates of locoregional (37.2 vs. 22.9%) and distant recurrence (13.3 vs. 7.0%) (p < 0.0001). Median OS was 27.3 months for CRT (95% CI: 23.6-32.4 months) and 47.5 months (95% CI: 39.6-52.1 months) for TL. Median DFS was 14.1 months for CRT (95% CI:12.5-17.2 months) and 37.9 months (95% CI 31.2-47.5 months) for TL. On multivariable analysis compared to CRT, TL was associated with longer time to locoregional (HR 0.50, 95% CI:0.40-0.61) and distant recurrence (HR 0.50, 95% CI:0.34-0.73). Having N+ disease increased risk of distant recurrence (HR 2.20, 95% CI:1.42-3.41). TL was associated with improved OS (HR 0.78, 95% CI:0.67 – 0.91), CSS (HR 0.73, 95% CI:0.59 – 0.89), and DFS (HR 0.58, 95% CI 0.49-0.69) compared to CRT; NCSS was equivalent between groups (HR 1.09, 95% CI:0.88-1.35). Of the CRT patients with locoregional failures, 67/163 (41.1%) were salvaged with surgery. Conclusions: In this cohort of T4a larynx cancer patients, surgical management demonstrated favorable recurrence and survival results. TL with adjuvant therapy was associated with significantly lower incidence of both locoregional and distant recurrence and increased OS, CSS and DFS compared to CRT. Lower probability of disease recurrence, in addition to a survival advantage, should be considered as an important advantage to up-front surgery.
Collapse
Affiliation(s)
| | | | | | | | - Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Edmund M. Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Alexander S. Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
6581 Background: Hospital readmission are associated with unfavorable patient outcomes and increased costs to the healthcare system. Devising interventions to reduce risks of readmission requires understanding patients at highest risk. Cancer patients represent a unique population with distinct risk factors. The purpose of this study was to define the impact of a cancer diagnosis on the risks of unplanned 30-day readmissions. Methods: We identified non-procedural hospital admissions between January through November 2017 from the National Readmission Database (NRD). We included patients with and without a cancer diagnosis who were admitted for non-procedural causes. We evaluated the impact of cancer on the risk of 30-day unplanned readmissions using multivariable mixed-effects logistic regression models. Results: Out of 18,996,625 weighted admissions, 1,685,099 (8.9%) had record of a cancer diagnosis. A cancer diagnosis was associated with an increased risk of readmission compared to non-cancer patients (23.5% vs. 13.6%, p < 0.001). However, among readmissions, cancer patients were less likely to have a preventable readmission (6.5% vs. 12.1%, p < 0.001). When considering the 10 most common causes of initial hospitalization, cancer was associated with an increased risk of readmission for each of these 10 causes (OR range 1.1-2.7, all p < 0.05) compared to non-cancer patients admitted for the same causes. Compared to patients aged 45-64, a younger age was associated with increased risk for cancer patients (OR 1.29, 95%CI [1.24-1.34]) but decreased risk for non-cancer patients (OR 0.65, 95%CI [0.64-0.66]). Among cancer patients, cancer site was the most robust individual predictor for readmission with liver (OR 1.47, 95%CI [1.39-1.55]), pancreas (OR 1.36, 95%CI [1.29-1.44]), and non-Hodgkin’s lymphoma (OR 1.35, 95%CI [1.29-1.42]) having the highest risk compared to the reference group of prostate cancer patients. Conclusions: Cancer patients have a higher risk of 30-day readmission, with increased risks among younger cancer patients, and with individual risks varying by cancer type. Future risk stratification approaches should consider cancer patients as an independent group with unique risks of readmission.
Collapse
Affiliation(s)
- Alexander Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Edmund Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | - James Don Murphy
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| |
Collapse
|
23
|
Qian AS, Qiao EM, Nalawade V, Voora RS, Kotha NV, Dameff C, Coyne CJ, Murphy JD. Impact of cancer on emergency department outcomes. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e18618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18618 Background: Cancer patients frequently utilize the Emergency Department (ED) for a variety of diagnoses, both related and unrelated to their cancer. Patients with cancer have unique risks related to their cancer and treatment which could influence ED-related outcomes. A better understanding of these risks could help improve risk-stratification for these patients and help inform future interventions. This study sought to define the increased risks cancer patients face for inpatient admission and hospital mortality among cancer patients presenting to the ED. Methods: From the National Emergency Department Sample (NEDS) we identified patients with and without a diagnosis of cancer presenting to the ED between 2016 and 2018. We used International Classification of Diseases, version 10 (ICD10-CM) codes to identify patients with cancer, and to identify patient’s presenting diagnosis. Multivariable mixed-effects logistic regression models assessed the influence of cancer diagnoses on two endpoints: hospital admission from the ED, and inpatient hospital mortality. Results: There were 340 million weighted ED visits, of which 8.3 million (2.3%) occurred in patients with a cancer diagnosis. Compared to non-cancer patients, patients with cancer had an increased risk of inpatient admission (64.7% vs. 14.8%; p < 0.0001) and hospital mortality (4.6% vs. 0.5%; p < 0.0001). Factors associated with both an increased risk of hospitalization and death included older age, male gender, lower income level, discharge quarter, and receipt of care in a teaching hospital. We identified the top 15 most common presenting diagnoses among cancer patients, and among each of these diagnoses, cancer patients had increased risks of hospitalization (odds ratio [OR] range 2.0-13.2; all p < 0.05) and death (OR range 2.1-14.4; all p < 0.05) compared to non-cancer patients with the same diagnosis. Within the cancer patient cohort, cancer site was the most robust individual predictor associated with risk of hospitalization or death, with highest risk among patients with metastatic cancer, liver and lung cancers compared to the reference group of prostate cancer patients. Conclusions: Cancer patients presenting to the ED have high risks for hospital admission and death when compared to patients without cancer. Cancer patients represent a distinct population and may benefit from cancer-specific risk stratification or focused interventions tailored to improve outcomes in the ED setting.
Collapse
Affiliation(s)
- Alexander S. Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Edmund M. Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | - Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Christian Dameff
- Department of Emergency Medicine, University of California, San Diego, La Jolla, CA
| | | | - James Don Murphy
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| |
Collapse
|
24
|
Kumar A, Cherry DR, Voora RS, Faraji F, Courtney PT, Finegersh A, Guo T, Cohen EE, Califano JA, Mell LK, Rose BS, Orosco RK. Transoral robotic surgery for human papillomavirus-associated oropharynx squamous cell carcinoma: Recurrence and survival in the Veterans Affairs health system. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.6054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6054 Background: Most transoral robotic surgery (TORS) literature comes from single and multi-institutional studies at tertiary-care academic intuitions. Long-term outcomes for patients with HPV-mediated oropharyngeal squamous cell carcinoma (HPV-OPSCC) treated with upfront TORS in other hospital settings across the United States are largely unknown. We present long-term recurrence and survival outcomes from a novel Veterans Health Administration (VHA) longitudinal dataset that includes patient-level data. Methods: Retrospective analysis of national VHA patients with p16-positive OPSCC diagnosed between January 2010 and December 2016, treated with TORS primary tumor resection with neck dissection. Outcome measures included: Cancer-specific survival (CSS), progression free survival (PFS), overall survival (OS), recurrence, extranodal extension (ENE), positive surgical margin (PSM), and adjuvant therapy regimen. Results: One hundred sixty-one patients were included of whom 29 (18%) were low-risk [0-1 metastatic lymph nodes, negative margins]; 45 (28%) intermediate-risk [close surgical margins, 2 to 4 metastatic nodes, LVI or PNI, pathologic T3 or T4 tumor]; and 87 (54%) high-risk [PSM, ENE, and/or ≥ 5 metastatic nodes]. ENE was present in 41% of cases and 24% of cases had positive surgical margins. Median follow-up was 5.6 years (95% CI 3.0-9.3). The 5-year CSS rates for low, intermediate, and high-risk groups were: 100%, 90.0% (95% CI 75.4-96.1%), and 88.7% (78.3-94.2%). On univariable analysis, pathologic factors associated with inferior CSS were: pT3-T4 tumor category (HR 3.81, 95% CI 1.31-11; p = 0.01), presence of more than four metastatic lymph nodes (HR 3.41, 95% CI 1.20-11; p = 0.02), and ENE (HR 3.53, 95% CI 1.06-12; p = 0.04). Close or PSM were not associated with CSS (HR 0.67, 95% CI 0.21 – 2.14; p = 0.50). In the low-risk group, 48% avoided adjuvant therapy and although there were five recurrences, none died from cancer. The intermediate-risk group was treated with adjuvant radiation in 64% of cases, and chemoradiation in 29% of cases; and there were five locoregional recurrences and three distant recurrences. Adjuvant chemoradiation was used in 68% of high-risk cases. Of the seven total patients with distant recurrences, six died of their disease. Conclusions: Our findings in this national cohort of Veterans with HPV-OPSCC demonstrate that TORS followed by adjuvant therapy yields favorable survival outcomes. Tumor-category, ENE, and more than four nodal metastases were the strongest adverse features in our data, and surgical margins did not have a significant impact on survival. Further investigations with large cohorts and prospective clinical trials are needed to elucidate the true oncologic implications of high-risk features and to identify patients best suited for de-intensified treatment.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Theresa Guo
- University of California, San Diego, San Diego, CA
| | | | | | | | | | | |
Collapse
|
25
|
Qiao E, Qian A, Nalawade V, Lee TC, Kotha NV, Voora RS, Dameff C, Coyne CJ, Murphy JD. Evaluating a high-dimensional machine-learning model to predict hospital mortality among elderly cancer patients. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.1512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1512 Background: Elderly hospitalized cancer patients face high risks of inpatient hospital mortality. Identifying patients at high risk of hospital mortality could help with risk stratification, and potentially help inform future interventions aimed at improving outcomes. We evaluated the predictive capacity of a high-dimensional machine-learning prediction tool to predict inpatient mortality, and compared the performance of this new tool to existing prediction indices. Methods: We identified cancer patients 75 and over who presented to an emergency department (ED) and were subsequently hospitalized from the National Emergency Department Sample (NEDS) between 2016 and 2018. We used an extreme gradient boosting approach to predict the risk of death during hospitalization. Model covariates included patient demographics, hospital characteristics, and International Classification of Diseases, version 10 (ICD-10) diagnosis codes recorded during the ED visit. The data were split 75%/25% into training/testing datasets. We constructed the model with training data and evaluated performance within the test data using area under the curve (AUC), with an AUC of 1.0 indicating perfect prediction. We compared the performance of this risk prediction model to standard prediction indices including the Hospital Frailty Risk Score, modified 5-item frailty index, and Charlson comorbidity index. Results: We identified 1,892,690 weighted-hospitalizations among elderly cancer patients, of which 133,379 (7.0%) who died in the inpatient setting. Our final predictive model included 238 features, which contained 5 demographic variables, 3 hospital characteristics, and 230 ICD-10 diagnosis codes. The predictive model achieved an AUC of 0.92. Our comparator models including the Hospital Frailty Risk Score, modified 5-item frailty index, and Charlson comorbidity index achieved AUCs of 0.67, 0.56, and 0.60, respectively. Conclusions: Using a high-dimensional machine-learning model enabled a high level of precision in predicting hospital mortality among elderly cancer patients, substantially out-performing existing prediction indices. High-dimensional prediction models show promise in helping to identify patients at risk of severe adverse outcomes, though additional validation is needed as well as research studying how to implement these tools into practice.
Collapse
Affiliation(s)
- Edmund Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Alexander Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Terrence C. Lee
- Department of Emergency Medicine, University of California, San Diego, La Jolla, CA
| | - Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | - Christian Dameff
- Department of Emergency Medicine, University of California, San Diego, La Jolla, CA
| | | | - James Don Murphy
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| |
Collapse
|
26
|
Qiao E, Kotha NV, Nalawade V, Qian A, Voora RS, Nelson TJ, Stewart TF, Parsons JK, Rose BS. Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.5004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5004 Background: African-American (AA) men are substantially more likely to present with lethal prostate cancer (PCa) at younger ages than non-Hispanic White men. Despite this disparity, AA men are poorly represented in the prostate-specific antigen (PSA) screening studies on which evidence-based PCa screening guidelines are based. This limits proper PSA screening guidance for AA men, especially for those younger than 55. We examined associations of PSA screening intensity with disease severity at diagnosis and prostate cancer-specific mortality (PCSM) in AA men < 55 years of age. Methods: The earliest recommended age to begin discussion of PSA screening is 40 years. We identified AA men aged 40-55 years, diagnosed with PCa from 2004 to 2017 within the Veterans Health Administration. PSA screening was identified using procedural codes. Screening intensity was defined as percentage of years screened within the pre-diagnostic observation period. This included up to 5 years prior to diagnosis. Multivariable logistic regression assessed the influence of PSA screening intensity on metastatic disease at diagnosis. Lead-time correction using published screening-dependent lead times was performed. PCSM was evaluated using Fine-Gray regression and non-cancer death as a competing event. Additional analysis was performed stratifying PSA screening into ‘High’ and ‘Low’ groups centered on the mean. Results: The cohort included 4,654 AA men at a mean age of 51.8 years with mean PSA screening rate of 53.2%. The pre-diagnostic observation period ranged from 1 to 5 years (median = 5 years). Median follow-up was 7 years. At diagnosis, there was a higher prevalence of Gleason sum ≥ 8 (Grade Group ≥ 4) and metastatic disease in the ‘Low’ group compared with the ‘High’ group ([Gleason sum ≥ 8 (Grade Group ≥ 4)]: 18.6% vs. 14.4%, p < 0.01; Metastatic disease at diagnosis: 3.7% vs. 1.4%, p < 0.01). Increased PSA screening intensity was associated with significantly reduced odds of metastatic disease at diagnosis (odds ratio: 0.61, 95% confidence interval (CI) = [0.47-0.81], p < 0.01) and decreased risk of PCSM (sub-distribution hazard ratio: 0.75, 95% CI = [0.59-0.95], p = 0.02). Conclusions: In this large national cohort of AA men aged 40 to 55 years, PSA screening increased intensity was associated with decreased risk of lethal disease and metastases at time of diagnosis and decreased PCSM. These data support the hypothesis that PSA screening and early prostate cancer detection may improve outcomes in younger AA men.
Collapse
Affiliation(s)
- Edmund Qiao
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Nikhil V. Kotha
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Vinit Nalawade
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | - Alexander Qian
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA
| | | | | | | | | | | |
Collapse
|
27
|
Voora RS, Kotha NV, Kumar A, Qiao EM, Qian AS, Panuganti BA, Banegas MP, Weissbrod PA, Stewart TF, Rose BS, Orosco RK. Association of race and health care system with disease stage and survival in veterans with larynx cancer. Cancer 2021; 127:2705-2713. [PMID: 33799314 DOI: 10.1002/cncr.33557] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Accepted: 02/01/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND Black patients with laryngeal squamous cell carcinoma (LSCC) historically have inferior outcomes in comparison with White patients. The authors investigated these racial disparities within the Veterans Health Administration (VHA), an equal-access system, and within the Surveillance, Epidemiology, and End Results (SEER) program, which is representative of the US hybrid-payer system. METHODS Patients with invasive (T1 or greater) LSCC were included from SEER (2004-2015) and the VHA (2000-2017). The primary outcomes of overall survival (OS) and larynx cancer-specific survival (LCS) were evaluated in Cox and Fine-Gray models. RESULTS In the SEER cohort (7122 patients: 82.6% White and 17.4% Black), Black patients were more likely to present with advanced disease and had inferior OS (hazard ratio [HR], 1.37; 95% CI, 1.26-1.50; P < .0001) in a multivariable analysis. Black LCS was worse in a univariable analysis (HR, 1.42; 95% CI, 1.27-1.58; P < .0001), but this effect was attenuated by 83% when the authors controlled for the TNM category and was found to be insignificant in a multivariable analysis (HR, 1.05; 95% CI, 0.93-1.18; P = .42). In the VHA cohort (9248 patients: 79.7% White and 20.3% Black), the 2 racial cohorts presented with similar tumor characteristics and similar OS (HR, 0.95; 95% CI, 0.89-1.02; P = .14). Black LCS was similar in univariable (HR, 1.10; 95% CI, 1.00-1.22; P = .05) and multivariable analyses (HR, 1.02; 95% CI, 0.92-1.14; P = .67). CONCLUSIONS Black patients with LSCC had a tumor burden at diagnosis and survival outcomes comparable to those of White patients within the VHA; this was counter to what was observed in the SEER analysis and prior national trends. This study's findings point toward the notable role of health care access in contributing to racial health disparities in the realm of larynx cancer.
Collapse
Affiliation(s)
- Rohith S Voora
- School of Medicine, University of California San Diego, San Diego, California.,Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California.,Veterans Affairs San Diego Healthcare System, San Diego, California
| | - Nikhil V Kotha
- School of Medicine, University of California San Diego, San Diego, California.,Veterans Affairs San Diego Healthcare System, San Diego, California.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California
| | - Abhishek Kumar
- Veterans Affairs San Diego Healthcare System, San Diego, California.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California
| | - Edmund M Qiao
- School of Medicine, University of California San Diego, San Diego, California.,Veterans Affairs San Diego Healthcare System, San Diego, California.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California
| | - Alexander S Qian
- School of Medicine, University of California San Diego, San Diego, California.,Veterans Affairs San Diego Healthcare System, San Diego, California.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California
| | - Bharat A Panuganti
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California.,Moores Cancer Center, La Jolla, California
| | | | - Philip A Weissbrod
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California.,Moores Cancer Center, La Jolla, California
| | - Tyler F Stewart
- Moores Cancer Center, La Jolla, California.,Division of Hematology-Oncology, University of California San Diego, San Diego, California.,Division of Blood and Marrow Transplantation, University of California San Diego, San Diego, California
| | - Brent S Rose
- Veterans Affairs San Diego Healthcare System, San Diego, California.,Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California.,Moores Cancer Center, La Jolla, California
| | - Ryan K Orosco
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California.,Veterans Affairs San Diego Healthcare System, San Diego, California.,Moores Cancer Center, La Jolla, California
| |
Collapse
|